IndieBio

About The Fund

IndieBio is an early-stage biotech venture capital firm and a part of the global venture capital firm SOSV, providing multi-stage investments with a focus on biology to engineer novel solutions across a wide range of industries. They invest in various sectors where biology plays a crucial role, including Software, Education, BioTech, AgroTech, Business Solutions, Energy, IoT (& Wearables), CleanTech, HealthTech (& Fitness), Food & Beverage, Impact, Insurance (& InsurTech), Material Science, Payments, DeepTech, Pharmaceutical (& Medicine), and Women Focused initiatives. IndieBio's mission is to support mission-driven startups with big ideas that aim to improve the world. With an initial investment of up to $525,000, their sweet spot matches their maximum investment capacity, positioning them as a significant early-stage funder. IndieBio's specialties include Pre-Seed, Seed, and Early Stage investments, and they are known for their pioneering work in early-stage biotech innovation, ranking as #1 in that domain. They have created over $12B in value through their 270 funded companies spanning 40 countries and boast a 42% rate of female founders among their investments. Operating in major innovation hubs such as San Francisco and New York, they emphasize diversity and consider their alumni network a great asset. Through events like Demo Days, Investor Panels, and Founder Fireside Chats, IndieBio cultivates an ecosystem where individuals can explore opportunities, gain employment in biotech, invest in biotech startups, or participate in mentorship programs. With over $1.6 billion in assets under management, SOSV and its program IndieBio focus on driving positive change while helping startups scale their ideas rapidly and effectively.